Search

everythinglearnresearchcommunity

for

Search:↓

People with diffuse thinning and retrograde hair loss are discussing treatments like finasteride, minoxidil, and dutasteride, with some reporting improvements and others experiencing issues like scalp inflammation and increased sebum. Suggestions include addressing scalp inflammation, considering gut health, and possibly using topical antiandrogens or micro-needling.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

Imidazole drugs like ketoconazole inhibit certain enzymes and prevent DHT from binding to SHBG, increasing free DHT in the bloodstream, which may contribute to balding. The discussion questions how these drugs help with hair loss despite this effect.

Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

Verteporfin is discussed as a potential treatment for scarring alopecia. Minoxidil is suggested as an alternative treatment.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The conversation discusses the link between increased estrogen and autoimmune diseases, with a focus on avoiding soy and milk. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.

The conversation discusses a leave-in ketoconazole product for hair loss, which is not commonly mentioned like Nizoral shampoo. One reply suggests it acts similarly to finasteride but with potential for low absorption and similar side effects.

Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hair loss, while castor oil is recommended to strengthen hair roots and reduce shedding.

A 38-year-old woman has been using oral Dutasteride for a year without improvement and is now adding a topical solution containing Minoxidil, Dutasteride, Tretinoin, Ketoconazole, and Hydrocortisone. She is seeking advice on whether switching from oral to topical Dutasteride could prevent hair shedding.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

The conversation discusses the lack of clinical studies on cysteine alone for hair loss, with the original poster already using medications like Minoxidil and finasteride. Suggestions include trying 2ddr as a growth stimulant, though concerns about side effects like gas are mentioned.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The conversation discusses using ketoconazole, an anti-androgen, for hair loss and whether mesotherapy with dermarolling could enhance its absorption into the scalp. The user questions if the typical 2% ketoconazole shampoo dose would be effective when used after dermarolling to target androgen receptors in the scalp.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

After 4 months of using topical finasteride and minoxidil, blood tests showed increased E2, Test, and Prolactine levels. The user is concerned about potential side effects like gyno and is seeking advice on managing these values.

A 23-year-old male switched to a topical solution containing Fin 0.1% and Min 5% from a previous solution with Fin 1% and Min 5%, noticing increased hair shedding. He is concerned about losing around 50 hairs while using ketoconazole shampoo.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

The user is experiencing hair improvement in the central and back areas after using finasteride, minoxidil, and a galenic lotion, but the temple area is worsening. They suspect the lotion might be causing the issue and are considering stopping its use.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

The user is experiencing one-sided diffuse thinning and has been using finasteride and liquid minoxidil for 4-5 years with minimal results. They are considering whether to save for a hair transplant or address scalp sensitivity and irritation first.